Hyalgan

Hyalgan is a prescription intra‑articular injection solution that contains sodium hyaluronate as its active ingredient. It is supplied in a sterile liquid form for direct administration into the knee joint. Marketed in the European Union, Hyalgan belongs to the hyaluronic acid (viscosupplement) class and is used as a symptomatic slow‑acting drug for osteoarthritis. The product provides joint lubrication by supplementing synovial fluid and improving joint movement.

Hyalgan is indicated for the management of knee osteoarthritis in adults when conservative therapies have not provided sufficient relief.

- Intra‑articular injection to supplement synovial fluid viscosity in the affected knee. - Adjunct to physical therapy and analgesic regimens for symptomatic relief. - Use in patients with mild to moderate radiographic osteoarthritis. - May be considered for individuals seeking a non‑surgical option to improve joint function. - Applicable in cases where NSAIDs are contraindicated or poorly tolerated.

Adverse reactions to intra‑articular Hyalgan are generally localized and may vary in frequency and severity.

Common: - Transient pain or swelling at the injection site that usually resolves within a few days. - Mild warmth or flushing in the treated knee during the first 24 hours. - Temporary stiffness or reduced range of motion lasting up to one week. - Mild headache that does not require specific treatment.

Serious: - Joint infection (septic arthritis) presenting with fever, severe pain, and purulent effusion, requiring antibiotics or surgical drainage. - Allergic reaction such as rash, urticaria, or angioedema that may need antihistamine or emergency care. - Severe joint effusion or persistent inflammation lasting more than two weeks. - Rapidly progressive osteoarthritis, a rare event characterized by accelerated cartilage loss.

Before initiating Hyalgan therapy, clinicians should evaluate patient history and joint condition to minimize risks.

- Avoid use in patients with active joint infection or systemic infection. - Do not inject into a joint with known hypersensitivity to hyaluronic acid preparations. - Assess for bleeding disorders; use caution in patients on anticoagulants. - Consider postponing treatment during pregnancy or lactation due to limited safety data. - Monitor for signs of infection or allergic reaction after each injection. - Limit the number of injections to the recommended course, typically three to five administrations.

Hyalgan may interact with other agents that affect joint health or bleeding risk; awareness of these interactions helps ensure safe use.

Avoid: - Concurrent intra‑articular corticosteroids or other viscosupplements in the same joint session. - Systemic antibiotics that mask early signs of joint infection.

Use with caution: - Anticoagulant or antiplatelet therapy, which may increase bleeding at the injection site. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that could exacerbate gastrointestinal irritation when combined with intra‑articular procedures. - Disease‑modifying osteoarthritis drugs (DMOADs) where overlapping mechanisms are not fully understood. - Biologic agents that modulate immune response, potentially altering infection risk.